USE OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR (EGFR) IN GEFITINIB RESISTANT PATIENTS.

摘要

This invention discloses method of treating or inhibiting cancer in a human having at least one of an Exon 19 del E746-A750 and/or an Exon 21 point mutation comprising administering to said human gefitinib and/or iressa alone or in combination with other cytotoxic agents or chemotherapeutic agents and an effective amount of EGFR kinase inhibitor.